Every 424B that 60 Degrees Pharmaceuticals, Inc. (SXTP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SXTP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SXTP filings page.
60 Degrees Pharmaceuticals amended its ATM prospectus to increase the offering capacity to $565,000. This figure gives effect to 325,200 shares previously sold for aggregate gross proceeds of $980,510.52 under the Sales Agreement with H.C. Wainwright & Co.
The supplement states shares outstanding were 2,472,949 and public float was $12,747,587 based on 2,451,459 shares held by non-affiliates and a closing price of $5.20 per share on January 28, 2026. The company effected a one-for-four reverse stock split on January 20, 2026. The last reported sale price on Nasdaq was $2.91 on March 12, 2026.
60 Degrees Pharmaceuticals, Inc. amends its at-the-market program to permit the offer and sale of up to $981,000 of common stock pursuant to the Sales Agreement with H.C. Wainwright & Co., LLC, March 11, 2026.
The $981,000 capacity reflects and includes 566,067 shares previously sold for aggregate gross proceeds of $1,307,508.15 under the Sales Agreement. The company reports a public float of $11,056,547 based on 2,147,749 outstanding shares, of which 2,126,259 were held by non-affiliates as of January 28, 2026. The company effected a one-for-four reverse stock split on January 20, 2026.
60 Degrees Pharmaceuticals amends its at-the-market program to register up to $1,308,000 of common stock pursuant to its September 5, 2025 Sales Agreement with H.C. Wainwright & Co., LLC.
The prospectus supplement updates the aggregate offering capacity to $1,308,000, excluding 555,593 shares previously sold for aggregate gross proceeds of $1,396,091. It states a public float of approximately $8,112,998 based on 1,581,682 shares outstanding as of January 28, 2026 and notes a one-for-four reverse stock split effective January 20, 2026. The filing cites the Form S-3 limitation that sales will not exceed one-third of public float in a 12-month period.